IQV
IQVIA Holdings Inc
NYSE: IQV · HEALTHCARE · DIAGNOSTICS & RESEARCH
$173.55
-1.84% today
Updated 2026-06-05
Market cap
$30.29B
P/E ratio
22.51
P/S ratio
1.82x
EPS (TTM)
$8.06
Dividend yield
—
52W range
$153 – $247
Volume
1.6M
WallStSmart proprietary scores
66
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B4.5
Quality
C6.5
Profitability
B6.7
Valuation
B2/9
Piotroski F-Score
Weak
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$230.56
+32.85%
12-Month target
$166.02
-4.34%
Intrinsic (DCF)
$194.83
Margin of safety
+9.06%
4 Strong Buy17 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 22.26% — strong efficiency
+ Free cash flow $491.00M — positive
+ Debt/equity 0.33x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.23 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $14.41B | $14.98B | $15.40B | $16.31B | $16.63B | $17.4B |
| Net income | $1.09B | $1.36B | $1.37B | $1.36B | $274.00M | — |
| EPS | — | — | — | — | $8.06 | $12.82 |
| Free cash flow | $1.59B | $1.50B | $2.11B | $2.05B | $491.00M | — |
| Profit margin | 7.57% | 9.06% | 8.91% | 8.34% | 8.33% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-07 | WIMS, MORRIS LESLIE | Buy | 171 | $178.64 |
| 2026-05-07 | GOGGINS, COLLEEN A | Buy | 214 | $178.64 |
| 2026-05-07 | FASANO, JIM | Buy | 228 | $178.64 |
Peer comparison
Smart narrative
IQVIA Holdings Inc trades at $173.55. representing a P/E of 22.51x trailing earnings. Our Smart Value Score of 66/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.23, it sits in the distress. TTM revenue stands at $16.63B. with profit margins at 8.33%. Our DCF model estimates intrinsic value at $194.83.
Frequently asked questions
What is IQVIA Holdings Inc's stock price?
IQVIA Holdings Inc (IQV) trades at $173.55, on a P/E of 22.5x and a P/S of 1.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is IQVIA Holdings Inc overvalued?
IQVIA Holdings Inc carries a Smart Value Score of 66/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $194.83 versus the $173.55 price, a 9.1% margin of safety on a cash flow basis.
What is the price target of IQVIA Holdings Inc (IQV)?
The 12-month analyst consensus target is $230.56, about 32.8% above the current $173.55. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of IQV by 2030?
Our research-backed model puts the 2030 base case at $1,559.34, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of IQVIA Holdings Inc (IQV)?
Our DCF model estimates intrinsic value at $194.83, a +9.1% margin of safety versus today's $173.55. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is IQVIA Holdings Inc's revenue?
IQVIA Holdings Inc's trailing twelve-month revenue is $16.63B, and our model projects it reaching about $21.95B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
IQVIA Holdings Inc's Altman Z-Score is 1.23, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio1.82x
ROE22.26%
Beta1.22
50D MA$173.09
200D MA$195.60
Shares out0.17B
Float0.16B
Short ratio—
Avg volume1.6M
Performance
1 week+0.00%
1 month+8.47%
3 months+11.37%
YTD-18.61%
1 year—
3 years—
5 years—